Medopa

Dopamine hydrochloride, the active ingredient in Medopa, is a vasoactive agent presented as an injectable solution for intravenous use. It supports cardiovascular function in patients with hypotension, shock, or low cardiac output. GNH USA supplies Medopa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Medopa (dopamine hydrochloride) acts on dopaminergic and adrenergic pathways to support cardiovascular function.

- Cardiogenic shock: improves myocardial contractility and raises blood pressure. - Septic shock: restores systemic vascular resistance and enhances renal perfusion. - Acute renal failure: increases renal blood flow to promote diuresis.

Adverse reactions may occur with intravenous dopamine administration.

Common Side Effects: - Tachycardia: rapid heart rate. - Arrhythmia: irregular cardiac rhythm. - Nausea or vomiting. - Headache. - Anxiety or restlessness. - Local infusion site irritation.

Serious or Rare Side Effects: - Myocardial ischemia: reduced heart muscle blood flow. - Severe hypertension: dangerously high blood pressure. - Tissue necrosis at infusion site. - Pulmonary edema: fluid accumulation in lungs. - Life‑threatening arrhythmias. - Extravasation injury leading to tissue damage.

Use of Medopa requires careful clinical monitoring. - Blood pressure monitoring: adjust infusion rate to maintain target pressures. - Cardiac rhythm observation: watch for arrhythmias, especially in patients with pre‑existing heart disease. - Renal function assessment: evaluate urine output and serum creatinine. - Dose titration: start low and increase gradually based on response. - Contraindications review: avoid in patients with pheochromocytoma or uncorrected tachyarrhythmias. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Dopamine may interact with several medications.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Beta‑blockers: may blunt dopamine’s inotropic effect. - Alpha‑adrenergic antagonists: may reduce vasoconstrictive response.

Moderate Interactions (Monitor Closely): - Diuretics: potential electrolyte disturbances. - ACE inhibitors or ARBs: additive blood pressure effects. - Other vasopressors: cumulative cardiovascular stimulation.